In an interview with PharmaShots, Dr. Ian Walters, CEO of Portage Biotech shared his views on the interim data from the P-II IT-01 trial evaluates the safety and efficacy of INT230-6 as both a monotherapy and in combination with pembrolizumab or ipilimumab in solid tumorsShots:The P-II IT-01 trial evaluates the safety & efficacy of INT230-6 as monothx. & in…
